Who owns ARDELYX, INC. (ARDX)? Elite investor 13F holders
3 tracked elite investors reported holding ARDELYX, INC as of 2026-06-30, including Rubric Capital, Renaissance Technologies LLC, D.E. Shaw. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
3 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Rubric Capital | ARDELYX INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 82633770.00 USD | 16202700.000000 | Shares | add | Original filing |
| Renaissance Technologies LLC | ARDELYX INC | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 4552224.00 USD | 892593.000000 | Shares | reduce | Original filing |
| D.E. Shaw | ARDELYX INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 66713.00 USD | 13081.000000 | Shares | reduce | Original filing |
| Tudor Investment | ARDELYX INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 0.00 USD | 0.000000 | Shares | exited | Original filing |
| Gotham Asset Management | ARDELYX INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 0.00 USD | 0.000000 | Shares | exited | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.